TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan -based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced ...

BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation ...

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals Business Wire Jun 9, 2025 ...

Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the Food and Drug Administration in 2024. APP13007's active ingredient is the superpotent corticosteroid, ...

When Gov. Glenn Youngkin of Virginia found out that Republican research had linked the G.O.P.’s nominee for lieutenant governor to a blog featuring photos of naked men, he tried to save his ...

TAIPEI, May 7, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ('Formosa', 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc.

TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc ...

Apotex Inc. (referred to as "Apotex" or "the Company") today announced it has entered into an exclusive licensing agreement with Formosa Pharmaceuticals ("Formosa", 6838.TW), for exclusive rights in ...